Treatment with troxerutin protects against cisplatin-induced kidney injury in mice.


Journal

Acta chirurgica Belgica
ISSN: 0001-5458
Titre abrégé: Acta Chir Belg
Pays: England
ID NLM: 0370571

Informations de publication

Date de publication:
Feb 2019
Historique:
pubmed: 15 4 2018
medline: 15 6 2019
entrez: 15 4 2018
Statut: ppublish

Résumé

Cisplatin (CP) is a synthetic and anticancer drug, and one of the major side effects of CP is nephrotoxicity. This study was done to evaluate the renoprotective effects of troxerutin (Tro) in nephrotoxicity induced by CP in male mice. In this experimental study, 28 male mice were divided randomly into four groups. Mice were treated with CP (20 mg/kg, i.p.) then Tro (75 and 150 mg/kg/day, po) was administered for three consecutive days. Blood samples were collected to determine serum creatinine (Cr) and blood urea nitrogen (BUN) levels. The kidney tissues were used for histological examination and biochemical assays. Malondialdehyde (MDA) level, superoxide dismutase (SOD) and glutathione peroxidase (GPx) activity were assessed in renal tissue. Results showed a significant increase in the Cr, BUN and MDA levels and a significant decrease in the renal SOD and GPx activity by CP administration. Treatment with Tro for three consecutive days attenuated these changes. Also, the renoprotective effect of the Tro was confirmed by the histological examination of the kidneys. Our results demonstrated that Tro has protective effects against CP-induced nephrotoxicity through improving the biochemical indices and the oxidative stress parameters.

Sections du résumé

BACKGROUND BACKGROUND
Cisplatin (CP) is a synthetic and anticancer drug, and one of the major side effects of CP is nephrotoxicity. This study was done to evaluate the renoprotective effects of troxerutin (Tro) in nephrotoxicity induced by CP in male mice.
METHODS METHODS
In this experimental study, 28 male mice were divided randomly into four groups. Mice were treated with CP (20 mg/kg, i.p.) then Tro (75 and 150 mg/kg/day, po) was administered for three consecutive days. Blood samples were collected to determine serum creatinine (Cr) and blood urea nitrogen (BUN) levels. The kidney tissues were used for histological examination and biochemical assays. Malondialdehyde (MDA) level, superoxide dismutase (SOD) and glutathione peroxidase (GPx) activity were assessed in renal tissue.
RESULTS RESULTS
Results showed a significant increase in the Cr, BUN and MDA levels and a significant decrease in the renal SOD and GPx activity by CP administration. Treatment with Tro for three consecutive days attenuated these changes. Also, the renoprotective effect of the Tro was confirmed by the histological examination of the kidneys.
CONCLUSIONS CONCLUSIONS
Our results demonstrated that Tro has protective effects against CP-induced nephrotoxicity through improving the biochemical indices and the oxidative stress parameters.

Identifiants

pubmed: 29653502
doi: 10.1080/00015458.2018.1455418
doi:

Substances chimiques

Anticoagulants 0
Antineoplastic Agents 0
Biomarkers 0
Hydroxyethylrutoside 0
troxerutin 7Y4N11PXO8
Cisplatin Q20Q21Q62J

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

31-37

Auteurs

Fereshteh Dehnamaki (F)

a Department of Biology , Payame Noor University , Tehran , Iran.

Akbar Karimi (A)

a Department of Biology , Payame Noor University , Tehran , Iran.

Ali Asghar Pilevarian (AA)

a Department of Biology , Payame Noor University , Tehran , Iran.

Iman Fatemi (I)

b Department of Physiology and Pharmacology , Rafsanjan University of Medical Sciences , Rafsanjan , Iran.
c Physiology-Pharmacology Research Center , Rafsanjan University of Medical Sciences , Rafsanjan , Iran.

Elham Hakimizadeh (E)

b Department of Physiology and Pharmacology , Rafsanjan University of Medical Sciences , Rafsanjan , Iran.
c Physiology-Pharmacology Research Center , Rafsanjan University of Medical Sciences , Rafsanjan , Iran.

Ayat Kaeidi (A)

b Department of Physiology and Pharmacology , Rafsanjan University of Medical Sciences , Rafsanjan , Iran.
c Physiology-Pharmacology Research Center , Rafsanjan University of Medical Sciences , Rafsanjan , Iran.

Mohammad Allahtavakoli (M)

b Department of Physiology and Pharmacology , Rafsanjan University of Medical Sciences , Rafsanjan , Iran.
c Physiology-Pharmacology Research Center , Rafsanjan University of Medical Sciences , Rafsanjan , Iran.

Mohammad Reza Rahmani (MR)

b Department of Physiology and Pharmacology , Rafsanjan University of Medical Sciences , Rafsanjan , Iran.
c Physiology-Pharmacology Research Center , Rafsanjan University of Medical Sciences , Rafsanjan , Iran.

Morteza Khademalhosseini (M)

d Department of Pathology , Rafsanjan University of Medical Sciences , Rafsanjan , Iran.

Gholamreza Bazmandegan (G)

c Physiology-Pharmacology Research Center , Rafsanjan University of Medical Sciences , Rafsanjan , Iran.
e Non-Communicable Diseases Research Center , Rafsanjan University of Medical Sciences , Rafsanjan , Iran.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH